248 related articles for article (PubMed ID: 32835443)
1. Unilateral versus bilateral sacral neuromodulation test in the treatment of refractory idiopathic overactive bladder: A randomized controlled pilot trial.
Wagner L; Alonso S; Le Normand L; Faix A; Kabani S; Castelli C; Gamé X; Cornu JN; Bey E
Neurourol Urodyn; 2020 Nov; 39(8):2230-2237. PubMed ID: 32835443
[TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
Amundsen CL; Richter HE; Menefee SA; Komesu YM; Arya LA; Gregory WT; Myers DL; Zyczynski HM; Vasavada S; Nolen TL; Wallace D; Meikle SF
JAMA; 2016 Oct; 316(13):1366-1374. PubMed ID: 27701661
[TBL] [Abstract][Full Text] [Related]
3. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
[TBL] [Abstract][Full Text] [Related]
4. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS).
Martin-Garcia M; Crampton J
Physiotherapy; 2019 Dec; 105(4):469-475. PubMed ID: 30862384
[TBL] [Abstract][Full Text] [Related]
5. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
[TBL] [Abstract][Full Text] [Related]
7. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.
Komesu YM; Amundsen CL; Richter HE; Erickson SW; Ackenbom MF; Andy UU; Sung VW; Albo M; Gregory WT; Paraiso MF; Wallace D;
Am J Obstet Gynecol; 2018 Jan; 218(1):111.e1-111.e9. PubMed ID: 29031894
[TBL] [Abstract][Full Text] [Related]
8. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
Richter HE; Moalli P; Amundsen CL; Malykhina AP; Wallace D; Rogers R; Myers D; Paraiso M; Albo M; Shi H; Nolen T; Meikle S; Word RA;
J Urol; 2017 Jun; 197(6):1487-1495. PubMed ID: 28089729
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Fluctuations in Treatment Response After OnabotulinumToxinA and Sacral Neuromodulation for Refractory Urgency Incontinence.
Hendrickson WK; Zhang C; Jelovsek JE; Nygaard IE; Presson AP
J Urol; 2024 Jan; 211(1):134-143. PubMed ID: 37871326
[TBL] [Abstract][Full Text] [Related]
10. Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged.
Firoozi F; Gill B; Ingber MS; Moore CK; Rackley RR; Goldman HB; Vasavada SP
J Urol; 2013 Aug; 190(2):594-7. PubMed ID: 23499745
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
Andy UU; Amundsen CL; Honeycutt E; Markland AD; Dunivan G; Dyer KY; Korbly NB; Bradley M; Vasavada S; Mazloomdoost D; Thomas S;
Am J Obstet Gynecol; 2019 Nov; 221(5):513.e1-513.e15. PubMed ID: 31211964
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of different electrical nerve stimulation protocols for treating adults with non-neurogenic overactive bladder: a systematic review and meta-analysis.
Zomkowski K; Kammers I; Back BBH; Moreira GM; Sonza A; Sacomori C; Sperandio FF
Int Urogynecol J; 2022 May; 33(5):1045-1058. PubMed ID: 35119495
[TBL] [Abstract][Full Text] [Related]
14. Specific Changes in Brain Activity during Urgency in Women with Overactive Bladder after Successful Sacral Neuromodulation: A Functional Magnetic Resonance Imaging Study.
Weissbart SJ; Bhavsar R; Rao H; Wein AJ; Detre JA; Arya LA; Smith AL
J Urol; 2018 Aug; 200(2):382-388. PubMed ID: 29630979
[TBL] [Abstract][Full Text] [Related]
15. Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity.
Shalom DF; Pillalamarri N; Xue X; Kohn N; Lind LR; Winkler HA; Metz CN
Am J Obstet Gynecol; 2014 Nov; 211(5):561.e1-5. PubMed ID: 25019486
[TBL] [Abstract][Full Text] [Related]
16. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
[TBL] [Abstract][Full Text] [Related]
17. Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence.
Richter HE; Amundsen CL; Erickson SW; Jelovsek JE; Komesu Y; Chermansky C; Harvie HS; Albo M; Myers D; Gregory WT; Wallace D;
J Urol; 2017 Oct; 198(4):890-896. PubMed ID: 28501541
[TBL] [Abstract][Full Text] [Related]
18. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.
Heesakkers JPFA; Digesu GA; van Breda J; Van Kerrebroeck P; Elneil S
Neurourol Urodyn; 2018 Mar; 37(3):1060-1067. PubMed ID: 28892221
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.
Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA
J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541
[TBL] [Abstract][Full Text] [Related]
20. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.
Abdel-Fattah M; Chapple C; Guerrero K; Dixon S; Cotterill N; Ward K; Hashim H; Monga A; Brown K; Drake MJ; Gammie A; Mostafa A; Bladder Health UK; Breeman S; Cooper D; MacLennan G; Norrie J
Trials; 2021 Oct; 22(1):745. PubMed ID: 34702331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
